

Akronym	Bezeichnung	Phase	Indikation	Beschreibung	Rekrutierung
IPF und PF-ILD STUDIEN					
Juniper	ND-L02s-0201-005	II	Idiopathische Lungenfibrose	A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Biological Activity, and PK of ND-L02-s0201 in Subjects with Idiopathic Pulmonary Fibrosis (IPF)	Aktiv
ZEPHYRUS	FibroGen FGCL-3019-091	III	Idiopathische Lungenfibrose	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects with Idiopathic Pulmonary Fibrosis (IPF)	Aktiv
Pliant	PLN-74809-IPF-202	IIa	Idiopathische Lungenfibrose	A randomized, double-blind dose-ranging, placebo-controlled Phase 2a evaluation of the safety, tolerability and pharmacokinetics of PLN-74809 in participants with idiopathic pulmonary fibrosis (IPF).	In Vorbereitung
BMS	IM027-040	II	Idiopathische Lungenfibrose	A Multicenter, randomized, double-blind, placebo-controlled, phase 2 study of the Efficacy and Safety and Tolerability of BMS-986278 in Participants with pulmonary Fibrosis.	Aktiv
Galactic	Galactic-1	IIb	Idiopathische Lungenfibrose	A randomized, double-blind, multicentre, parallel, placebo-controlled Phase 2b study in subjects with idiopathic pulmonary fibrosis (IPF) investigating the efficacy and safety of TD139, an inhaled galectin-3 inhibitor administered via a dry powder inhaler over 52 weeks.	Aktiv
Roche	WA-42293	III	Idiopathische Lungenfibrose	A Phase III Randomized, Double –Blind, placebo-controlled trial to evaluate the efficacy and Safety of PRM-151 in patients with idiopathic pulmonary fibrosis.	In Vorbereitung

Inreal	NIS 1199-0449	NA	Idiopathische Lungenfibrose	Prospective observational investigation of possible correlations between change in FVC and change in cough or dyspnea scores using the living with pulmonary fibrosis questionnaire (L-PF) between baseline and after approximately 52 weeks of nintedanib treatment in patient suffering from chronic fibrosing ILD with a progressive phenotype.	Aktiv
Alveolar Proteinose STUDIEN					
IMPALA 2	IMPALA MOL PAP	III	Alveolar Proteinose	A randomized, Double Blind, Placebo-controlled Clinical trial of once-daily inhaled Molgramostim nebulizer solution in adult subjects with autoimmune Alveolar-Proteinosis (aPAP)	In Vorbereitung
Sarkoidose STUDIEN					
Novartis	CCMK389X2201	II	Sarkoidose	A subject and investigator blinded, randomized, placebocontrolled, repeat-dose, multicenter study to investigate efficacy, safety, and tolerability of CMK389 in patients with chronic pulmonary sarcoidosis.	Aktiv